查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1834038

儿童失神癫痫治疗市场（按治疗类型、药物类别、最终用户和分销管道）—2025 年至 2032 年全球预测

Childhood Absence Epilepsy Treatment Market by Treatment Type, Drug Class, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，儿童失神癫痫治疗市场规模将成长至 4.6047 亿美元，复合年增长率为 7.65%。

主要市场统计数据
基准年2024年 2.5522亿美元
预计2025年 2.7462亿美元
预测年份：2032年 4.6047亿美元
复合年增长率（%） 7.65%

简要概述临床重点、不断发展的诊断准确性以及影响儿童失神癫痫管理策略的多方面治疗方法

儿童失神癫痫是一种独特的临床疾病，其特征是短暂、频繁的失神发作，最常见于学龄儿童，需要高度个人化的治疗策略。临床医生、看护者和医疗保健系统必须在控制癫痫发作的同时，兼顾神经发育结局、认知副作用和长期安全性。近年来，临床实践已从单纯关注即时癫痫发作抑制发展到更广泛地关注认知功能、耐受性和生活品质的保留。

因此，治疗策略已将药物、饮食和神经调节方法结合起来，每种方法都有其独特的风险-效益特征，影响临床决策。诊断准确性的同步提高，包括更便捷的门诊脑电图和更精细的电临床表型，改善了诊断和亚型的划分，从而提供了更有针对性的治疗方法方案。本引言概述了临床重点，并以此为基础构建了以下章节：优化长期神经认知结局，最大限度地减少关键发展阶段的副作用，并确保在不同的医疗保健机构中公平地获得循证医疗服务。

诊断创新、数位化医疗服务和多学科方法如何重塑儿童失神癫痫的治疗方案和治疗途径

由于技术创新、临床指南的不断演变以及对个人化治疗的重新重视，儿童失神癫痫的治疗格局正在发生重大变化。门诊和可穿戴脑电图 (EEG) 技术的进步提高了诊断准确性，并使得能够更早发现潜在的癫痫发作负担。同时，数位健康平台和远端医疗扩展了追踪能力，使得在传统门诊就诊之外，能够更频繁地监测患者的认知结果和耐受性。

虽然药物治疗仍是核心，但其机制见解和安全性数据正日益成为影响乙琥胺、拉莫三嗪、左乙拉西坦和丙戊酸选择的重要因素。同时，人们对非药物治疗策略（结构化饮食和标靶神经刺激）的兴趣日益浓厚，促使整合神经病学、营养医学和神经心理学的多学科治疗模式应运而生。监管和支付方格局也在不断调整，更加重视真实世界证据，以支持药品标籤扩展和覆盖范围决策。这些因素共同重塑了临床医生的行为、转诊模式和比较有效性研究的设计，最终旨在使治疗方法选择与发展目标和以患者为中心的治疗结果一致。

评估美国近期关税变化如何影响供应链弹性、筹资策略以及儿童失神性癫痫基本治疗的获取模式

美国2025年关税政策的调整对支持儿童失神性癫痫治疗的供应链产生了明显的连锁反应，尤其是那些依赖进口活性药物原料药、专用医疗设备和膳食配方成分的领域。医院和专科诊所的采购团队正在采取应对措施，审查供应商关係，探索替代采购方案，并优先考虑库存弹性，以缓解突发中断的影响。同时，製造商和经销商正在重新评估其成本结构和物流策略，以吸收和分配增加的进口相关成本，同时保持对临床医生和家庭的持续供应。

临床医生和医疗系统药剂师表示，他们更加关注产品原产地和可互换性，并且在有多种治疗方案可供选择时，选择标准也更加谨慎。面对日益增长的关税压力，医疗设备供应商正在加快就本地製造、零件替代以及保护采购方免受进口成本波动影响的合约保护措施展开讨论。重要的是，付款人和医疗系统采购团队正在仔细审查这些措施对总护理成本的影响，包括潜在供应中断对门诊病人监测和住院观察服务的营运影响。这些累积效应正在推动对多元化采购、製造商和医疗保健提供者之间更紧密合作以及积极主动的风险分担机制的策略需求，这些机制旨在确保患者能够获得成熟的治疗方法和辅助技术。

详细的细分驱动洞察解释了治疗方式、药物类别、医疗保健环境和通路如何相互作用，从而影响治疗决策和交付

深入的細項分析揭示了不同治疗类型、药物类别、最终用户和通路在临床应用、护理提供和购买行为方面的显着差异。治疗类型包括抗癫痫药物、饮食疗法和神经刺激疗法。对于抗癫痫药物，临床医生通常会在乙琥胺、拉莫三嗪、左乙拉西坦和丙戊酸之间进行选择，每种药物对认知发育的疗效和耐受性各不相同。同时，神经刺激疗法，例如深部脑部刺激和迷走神经刺激，通常用于难治性或复杂病例，需要操作和设备管理技能。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩展整合基因组分析的精准医疗方法
  • 开发长效抗癫痫药物製剂以提高儿科患者的用药依从性
  • 采用真实世界证据研究来评估失神癫痫治疗的比较有效性和安全性
  • 整合人工智慧脑电图模式识别工具，实现早期诊断与治疗优化
  • 新型 GABA 受体调节剂的出现解决了儿童失神性癫痫治疗中的抗药性问题
  • 增加以大麻二酚和其他大麻素衍生物为重点的儿科神经病学临床试验的投资
  • 生技公司与学术机构加强合作，探索儿童失神性癫痫的治疗方法

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 儿童失神癫痫治疗市场（依治疗类型）

  • 抗癫痫药物
    • 乙琥胺
    • 拉莫三嗪
    • 左乙拉西坦
    • 丙戊酸
  • 饮食疗法
    • 生酮饮食
    • 改良阿特金森疗法
  • 神经刺激
    • 深部脑部刺激
    • 迷走神经刺激

9. 儿童失神癫痫治疗市场（依药物类别）

  • 乙琥胺
  • 拉莫三嗪
  • 左乙拉西坦
  • 丙戊酸

第 10 章。儿童失神癫痫治疗市场（按最终用户）

  • 居家照护环境
    • 看护者管理
    • 居家护理
  • 医院
    • 住院病人
    • 门诊
  • 专科诊所
    • 癫痫监测单元
    • 儿科神经学中心

第 11 章儿童失神癫痫治疗市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

12. 儿童失神癫痫治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章儿童失神癫痫治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 儿童失神癫痫治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • GlaxoSmithKline plc
    • UCB SA
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
Product Code: MRR-433AB1DC2923

The Childhood Absence Epilepsy Treatment Market is projected to grow by USD 460.47 million at a CAGR of 7.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 255.22 million
Estimated Year [2025] USD 274.62 million
Forecast Year [2032] USD 460.47 million
CAGR (%) 7.65%

A concise overview of clinical priorities, evolving diagnostic precision, and the multifaceted treatment approaches shaping childhood absence epilepsy management strategies

Childhood absence epilepsy presents a unique clinical profile characterized by brief, frequent absence seizures that predominantly affect school-aged children and demand highly individualized management strategies. Clinicians, caregivers, and health systems must balance seizure control against neurodevelopmental outcomes, cognitive side effects, and long-term safety considerations. Over recent years, clinical practice has evolved from a narrow emphasis on immediate seizure suppression to a broader focus on cognitive preservation, tolerability, and quality of life, driven by accumulating comparative effectiveness evidence and heightened attention to developmental trajectories.

Consequently, treatment pathways now incorporate a spectrum of pharmacologic, dietary, and neuromodulatory approaches, each with distinct risk-benefit profiles that influence clinical decision-making. Parallel advances in diagnostic precision, including more accessible ambulatory electroencephalography and refined electroclinical phenotyping, have improved diagnosis and subtyping, thereby enabling more targeted therapeutic selection. This introduction frames the subsequent sections by outlining the persistent clinical priorities: optimizing long-term neurocognitive outcomes, minimizing adverse effects during critical developmental windows, and ensuring equitable access to evidence-informed care across diverse health delivery settings.

How diagnostic innovation, digital care delivery, and multidisciplinary approaches are reshaping treatment selection and care pathways for childhood absence epilepsy

The landscape of childhood absence epilepsy treatment is experiencing transformative shifts driven by technological innovations, evolving clinical guidelines, and a renewed emphasis on individualized care. Advances in ambulatory and wearable electroencephalographic technologies are enhancing diagnostic granularity and enabling earlier detection of subclinical seizure burden. At the same time, digital health platforms and telemedicine are expanding follow-up capacity, permitting more frequent monitoring of cognitive outcomes and tolerability outside traditional clinic visits.

Pharmacotherapy remains central but is increasingly contextualized by mechanistic insights and safety data, which influence the choice among ethosuximide, lamotrigine, levetiracetam, and valproate. Concurrently, interest in nonpharmacologic strategies-structured dietary regimens and targeted neurostimulation-has grown, prompting multidisciplinary care models that integrate neurology, nutritional medicine, and neuropsychology. Regulatory and payer environments are also adapting, with a greater focus on real-world evidence to support label expansions and coverage decisions. Together, these forces are reshaping clinician behavior, referral patterns, and the design of comparative effectiveness studies, ultimately aiming to align therapeutic selection with developmental goals and patient-centered outcomes.

Assessment of how recent United States tariff changes are influencing supply chain resilience, procurement strategies, and access patterns for childhood absence epilepsy care essentials

The 2025 adjustments in United States tariff policy have had a notable ripple effect across the supply chains that support treatments for childhood absence epilepsy, particularly in areas reliant on imported active pharmaceutical ingredients, specialized medical devices, and dietary formulation components. Procurement teams in hospitals and specialty clinics have responded by reassessing vendor relationships, seeking alternative sourcing arrangements, and prioritizing inventory resilience to mitigate episodic disruptions. In parallel, manufacturers and distributors are revisiting cost structures and logistics strategies to absorb and allocate incremental import-related costs while maintaining continuity of supply for clinicians and families.

Clinicians and health system pharmacists have reported greater attention to product origin and interchangeability, leading to more deliberate selection criteria when multiple therapeutic options are available. Device suppliers facing tariff pressures have accelerated conversations about local production, component substitution, and contractual protections that insulate purchasers from volatile import expenses. Importantly, payers and health system procurement teams are scrutinizing total cost of care implications, including the operational impact of potential supply interruptions on outpatient monitoring and inpatient observation practices. These cumulative effects reinforce the strategic need for diversified sourcing, closer collaboration between manufacturers and care providers, and proactive risk-sharing mechanisms that preserve patient access to established therapies and adjunctive technologies.

Detailed segmentation-driven insights illustrating how treatment modalities, drug classes, care settings, and distribution pathways interact to shape therapeutic decision-making and delivery

Insightful segmentation analysis reveals meaningful differences in clinical application, care delivery, and purchasing behavior across treatment types, drug classes, end users, and distribution channels. Based on treatment type, the therapeutic landscape encompasses anti-seizure medication, dietary therapy, and neurostimulation; within anti-seizure medication, clinicians commonly navigate choices among ethosuximide, lamotrigine, levetiracetam, and valproate, each presenting distinct efficacy and tolerability considerations for cognitive development. Dietary therapy pathways include classical ketogenic diets and modified Atkinson regimens that require structured implementation and ongoing nutritional oversight, while neurostimulation options such as deep brain stimulation and vagus nerve stimulation are typically reserved for refractory or complex presentations and entail procedural and device management competencies.

Based on drug class considerations, prescribers weigh mechanism-specific adverse event profiles and developmental safety when selecting ethosuximide, lamotrigine, levetiracetam, or valproate for initial or adjunctive regimens. Based on end user, treatment delivery varies among home care settings, hospitals, and specialty clinics; home care settings include both caregiver-managed regimens and home nursing support that emphasize adherence and remote monitoring, hospitals encompass inpatient and outpatient workflows that support acute evaluation and titration, and specialty clinics comprised of epilepsy monitoring units and pediatric neurology centers focus on complex diagnostics and interdisciplinary care planning. Based on distribution channel, acquisition and dispensing occur via hospital pharmacies, online pharmacies, and retail pharmacies, each channel presenting distinct workflows for prior authorization, patient counseling, and medication reconciliation. Synthesizing these segmentation dimensions highlights how clinical decision-making, logistical constraints, and care setting capabilities collectively shape therapeutic pathways and downstream resource needs.

Regional variation in care models, regulatory pathways, and cultural acceptance that influences adoption, access, and clinical decision-making across global healthcare environments

Regional dynamics shape how childhood absence epilepsy is detected, managed, and resourced across different health systems and cultural contexts. In the Americas, care models often integrate pediatric neurology networks with established hospital infrastructure and growing telemedicine capabilities that support follow-up and remote monitoring; payer and formulary policies influence therapeutic choice, and there is active clinical dialogue about neurodevelopmental outcomes alongside seizure control. In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable access to specialized services create diverse care pathways, with some countries offering robust specialty clinic networks while others rely on decentralized models where primary care clinicians play a larger role in initial management.

In the Asia-Pacific region, accelerating adoption of digital diagnostics and expanding specialty capacity coexist with varied reimbursement environments and differing dietary practice acceptance, which affects the practical uptake of ketogenic regimens. Across all regions, cultural perceptions of dietary interventions, device-based therapies, and long-term pharmacotherapy influence caregiver acceptance and adherence. Moreover, regional regulatory review processes and approval timelines for devices and label updates for medications contribute to differences in available therapeutic options, while cross-border collaborations and knowledge exchange continue to narrow clinical practice variation through shared guidelines and multicenter research initiatives.

Competitive and collaborative company strategies focused on safety evidence, service delivery innovation, and supply chain resilience across pharmacologic, device, and dietary therapy segments

Key companies operating across the childhood absence epilepsy ecosystem are pursuing differentiated strategies that span product lifecycle management, evidence generation, and service delivery partnerships. Pharmaceutical manufacturers maintain portfolios that include both originator and generic anti-seizure medications, and their strategies increasingly emphasize safety data in pediatric populations and label clarity to support prescriber confidence. Device firms focused on neuromodulation are investing in usability, smaller form factors, and clinician training programs to broaden the procedural base and improve long-term device management outcomes. Additionally, organizations that provide structured dietary therapy services are formalizing multidisciplinary protocols, dietitian certification pathways, and remote support tools to scale implementation while safeguarding nutritional monitoring.

Strategic activity also includes academic and industry collaborations to produce comparative effectiveness research and registries that capture cognitive and developmental endpoints. Commercial players are exploring value-based contracting models with health systems to align reimbursement with functional outcomes rather than short-term seizure counts. Supply chain adaptation has prompted manufacturers and distributors to strengthen supplier diversification and to explore regional manufacturing partnerships. Taken together, these company-level initiatives reflect a market environment that prizes evidence-based differentiation, clinician support infrastructure, and scalable models for delivering multidisciplinary care.

Actionable strategic priorities for industry leaders to strengthen evidence generation, clinician enablement, supply chain resilience, and patient-centered delivery models

Industry leaders should prioritize integrated strategies that bridge clinical evidence generation with practical deployment across care settings to advance outcomes for children with absence epilepsy. First, invest in comparative and long-term observational studies that center cognitive and developmental outcomes as primary endpoints, and use these data to inform label clarity, prescribing guidelines, and payer dialogues. Second, strengthen clinician and caregiver education programs that translate nuanced benefit-risk profiles into day-to-day clinical decision tools, enabling personalized therapy selection and adherence support in both specialty clinics and home care environments.

Operationally, companies and health systems should diversify sourcing and localize critical components where feasible to reduce exposure to tariff-driven disruptions. Concurrently, expand digital monitoring and telehealth capabilities to support remote titration, nutritional counseling for dietary regimens, and device follow-up, thereby reducing the burden on in-person services. Finally, pursue collaborative reimbursement models that link payments to meaningful functional outcomes, invest in scalable dietary therapy infrastructures, and cultivate partnerships with academic centers to accelerate high-quality evidence generation. Collectively, these actions will align commercial priorities with clinical imperatives and improve continuity of care for affected children.

Mixed-methods research approach combining guideline review, expert interviews, clinical literature synthesis, and supply chain assessment to ensure robust and actionable insights

This research synthesis was developed through a mixed-methods approach that combined systematic literature review, expert stakeholder interviews, clinical guideline analysis, and supply chain evaluation to produce a cohesive picture of treatment dynamics. Peer-reviewed clinical literature and contemporary guideline statements were reviewed to identify prevailing clinical practices, safety signals, and areas of diagnostic evolution, while expert interviews with pediatric neurologists, dietitians, hospital pharmacists, and procurement leaders provided grounded insights into implementation challenges and operational realities.

Complementing clinical inputs, an analysis of distribution channels and procurement behaviors illuminated how hospitals, specialty clinics, and home care programs acquire therapies and support adherence. Data triangulation and iterative validation sessions with clinical advisors were used to reconcile divergent perspectives and ensure that thematic conclusions reflect practice-level variation. Quality assurance measures included cross-referencing multiple independent sources and reconciling terminology across therapeutic modalities to maintain clarity and reproducibility in the final synthesis.

Strategic synthesis highlighting the necessity of evidence-aligned care pathways, multidisciplinary delivery models, and resilient procurement to improve childhood absence epilepsy outcomes

The collective analysis underscores that optimizing care for childhood absence epilepsy requires harmonizing clinical evidence, delivery capabilities, and supply chain resilience. Pharmacologic therapies remain foundational, yet their selection increasingly reflects a balance between seizure control and neurodevelopmental safety. Nonpharmacologic modalities-structured dietary therapy and selective neurostimulation-play complementary roles when tailored to individual clinical profiles and supported by multidisciplinary teams. Concurrently, diagnostic and digital innovations are enhancing monitoring and enabling more proactive management outside conventional clinic settings.

Stakeholders must therefore commit to evidence-driven practice, strengthen systems for remote monitoring and dietetic support, and cultivate resilient procurement strategies that mitigate external shocks. By aligning clinical priorities with operational capabilities and strategic investments in evidence generation, healthcare organizations and commercial entities can improve functional outcomes and support sustained access to appropriate therapies for children living with absence epilepsy. This synthesis serves as a foundation for focused strategic planning and collaborative action across the ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of precision medicine approaches integrating genomic profiling in childhood absence epilepsy treatment
  • 5.2. Development of long-acting antiepileptic drug formulations targeting improved compliance in pediatric patients
  • 5.3. Adoption of real-world evidence studies to evaluate comparative efficacy and safety of absence epilepsy therapies
  • 5.4. Integration of AI-powered EEG pattern recognition tools for early diagnosis and treatment optimization
  • 5.5. Emergence of novel GABA receptor modulators addressing drug resistance in childhood absence epilepsy management
  • 5.6. Increasing investment in pediatric neurology clinical trials focusing on cannabidiol and other cannabinoid derivatives
  • 5.7. Growing collaboration between biotech firms and academic centers for pediatric absence epilepsy drug discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Childhood Absence Epilepsy Treatment Market, by Treatment Type

  • 8.1. Anti-Seizure Medication
    • 8.1.1. Ethosuximide
    • 8.1.2. Lamotrigine
    • 8.1.3. Levetiracetam
    • 8.1.4. Valproate
  • 8.2. Dietary Therapy
    • 8.2.1. Ketogenic Diet
    • 8.2.2. Modified Atkinson Regimen
  • 8.3. Neurostimulation
    • 8.3.1. Deep Brain Stimulation
    • 8.3.2. Vagus Nerve Stimulation

9. Childhood Absence Epilepsy Treatment Market, by Drug Class

  • 9.1. Ethosuximide
  • 9.2. Lamotrigine
  • 9.3. Levetiracetam
  • 9.4. Valproate

10. Childhood Absence Epilepsy Treatment Market, by End User

  • 10.1. Home Care Settings
    • 10.1.1. Caregiver Managed
    • 10.1.2. Home Nursing
  • 10.2. Hospitals
    • 10.2.1. Inpatient
    • 10.2.2. Outpatient
  • 10.3. Specialty Clinics
    • 10.3.1. Epilepsy Monitoring Units
    • 10.3.2. Pediatric Neurology Centers

11. Childhood Absence Epilepsy Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Childhood Absence Epilepsy Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Childhood Absence Epilepsy Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Childhood Absence Epilepsy Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. GlaxoSmithKline plc
    • 15.3.3. UCB S.A.
    • 15.3.4. Sanofi S.A.
    • 15.3.5. Sun Pharmaceutical Industries Ltd.
    • 15.3.6. Teva Pharmaceutical Industries Ltd.
    • 15.3.7. Viatris Inc.
    • 15.3.8. Pfizer Inc.
    • 15.3.9. Johnson & Johnson
    • 15.3.10. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS,